Symbols

WST

West Pharmaceutical·NYSE

--(--)

WST fundamentals

WST Q4 2025 Earnings

West Pharmaceutical (WST) released its earnings on Feb 12, 2026: revenue was 805.00M (YoY +7.51%), beat estimates; EPS was 2.04 (YoY +12.09%), beat estimates.

Revenue / YoY

805.00M

+7.51%

EPS / YoY

2.04

+12.09%

Report date

Feb 12, 2026

WST Earnings Call Summary for Q4,2025

Q4 Revenue Beat: $805M (+7.5% reported, 3.3% organic), driven by 15.1% HVP components growth.
EPS & Cash Flow Strength: Adjusted EPS $2.04 (+12%), free cash flow $469M (70% YoY growth).
GLP-1 Outlook: 10% 2026 growth midpoint, conservative vs. 50%+ 2025 expansion.
Strategic Moves: SmartDose sale midyear, $250M-$275M 2026 CapEx for HVP capacity.
Annex 1 Growth: 200+ bps 2026 contribution from 6B component upgrades.

Earnings

EPS

Revenue

Revenue & Expenses

WST has released its 2025 Q4 earnings report, with revenue of 805.00M, reflecting a YoY change of 7.51%, and net profit of 132.10M, showing a YoY change of 1.54%. The Sankey diagram below clearly presents WST's revenue sources and cost distribution.

Key Indicators

West Pharmaceutical (WST) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

West Pharmaceutical (WST)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

West Pharmaceutical (WST)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

West Pharmaceutical (WST)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown